EUVIMEDOpdag EUVIMED
BeobachtungsstudieOpen access · CC BY 4.0

Impact of Elexacaftor‐Tezacaftor‐Ivacaftor on Quality of Life in Children With Cystic Fibrosis

Sara Kümmerli iD, Clara Fernandez Elviro, Nicolas Regamey iD, Anne Mornand, Mohamed Faouzi, Isabelle Rochat iD, Sylvain Blanchon iD

Pediatric Pulmonology · 2026-01 · 61 (1)

DOI: 10.1002/ppul.71461 ↗

At a glance

Beobachtungsstudie in Pediatric Pulmonology, published online on 2026-01-07. Written by Sara Kümmerli and 6 co-authors. Institution: Pediatric Pulmonology and Cystic Fibrosis Unit, Division of Pediatrics, Department Woman-Mother-Child, Lausanne University Hospital and University of…. Major MEDLINE topics: Cystic Fibrosis, Quality of Life, Aminophenols, Quinolones. Cited 4 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY 4.0). Funded by: Cystic Fibrosis Switzerland, Fondation Respirer.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objectives

CFTR modulators have revolutionized cystic fibrosis (CF) management by targeting the defective protein rather than its consequences. Their impact on quality of life (QoL) have been studied in numerous trials, but few data are available on QoL in patients receiving Elexacaftor‐Tezacaftor‐Ivacaftor (ETI), notably in children given its recent authorization for this age group. We aimed to assess the impact of ETI on children's QoL.

Methods

This prospective observational study included children with CF (6−17 years), assessing QoL using the CF Questionnaire Revised (CFQ‐R) before (baseline) and 3 months after (M3) starting ETI treatment for children and their caregivers.

Results

We included 23 children (median [range]) age 10.2 [6−17.2] years, 13 (57%) with homozygous F508del genotype. The total QoL score at baseline ([mean (SD)] children: 74.07 [10.86]; caregivers: 73.21 [10.38]) reflected severe disease impact, particularly regarding treatment burden in the children's perspective (63.28 [21.04]) and digestive domains in the caregivers' perspective (digestive symptoms: 66.67 [17.37]; eating disorder: 67.54 [32.14]; weight: 61.40 [33.82]). At M3, there was a significant increase in reported QoL ( p = 0.0001), particularly regarding physical domains. Emotional/social/school domains barely showed improvement. Although QoL mean scores were comparable between children and caregivers' groups, they were poorly correlated within the same family. Homozygous F508del genotype was associated with better QoL improvement at M3 compared to composite heterozygous genotypes ( p < 0.001).

Conclusion

ETI treatment has a significant impact on children's QoL, particularly in physical health domains. Other QoL domains that are not improved by ETI need to be addressed, in particular, psycho‐social components. Both children's and caregivers' perspectives must be considered for a holistic picture of children's QoL.

Subjects

MeSH terms (MEDLINE)

Cystic FibrosisQuality of LifeAminophenolsQuinolonesBenzodioxolesIndolesPyrazolesPyridinesPyrrolidinesAcetanilidesHumansChildMaleFemaleAdolescentProspective StudiesDrug CombinationsSurveys and QuestionnairesCaregiversCystic Fibrosis Transmembrane Conductance RegulatorChloride Channel AgonistsTreatment OutcomeQuinolines

Author keywords

CFTR modulatorElexacaftor‐Tezacaftor‐Ivacaftorchildrencystic fibrosis (CF)cystic fibrosis quality of life questionnaire (CFQ‐R)quality of life

Substances

AminophenolsQuinolonesDrug CombinationsBenzodioxolesIndolesPyrazolesPyridinesPyrrolidineselexacaftor, ivacaftor, tezacaftor drug combinationAcetanilides

Authors and institutions

  • Pediatric Pulmonology and Cystic Fibrosis Unit, Division of Pediatrics, Department Woman-Mother-Child, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Pediatric Pulmonology and Cystic Fibrosis Unit, Children's Hospital of Central Switzerland, Lucerne, Switzerland.
  • Pediatric Pulmonology and Cystic Fibrosis Unit, University Hospital of Geneva, Geneva, Switzerland.
  • Division of Biostatistics, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.

ORCID profiles: Sara Kümmerli, Nicolas Regamey, Isabelle Rochat, Sylvain Blanchon

Funding

  • Cystic Fibrosis Switzerland
  • Fondation Respirer

Cite

APA

Kümmerli, S., Elviro, C. F., Regamey, N., Mornand, A., Faouzi, M., Rochat, I., & Blanchon, S. (2026). Impact of Elexacaftor‐Tezacaftor‐Ivacaftor on Quality of Life in Children With Cystic Fibrosis. Pediatric Pulmonology, 61(1). https://doi.org/10.1002/ppul.71461

Vancouver

Kümmerli S, Elviro CF, Regamey N, Mornand A, Faouzi M, Rochat I, et al. Impact of Elexacaftor‐Tezacaftor‐Ivacaftor on Quality of Life in Children With Cystic Fibrosis. Pediatric Pulmonology. 2026;61(1). doi:10.1002/ppul.71461

BibTeX
@article{Kmmerli2026,
  author = {Kümmerli, Sara and Elviro, Clara Fernandez and Regamey, Nicolas and Mornand, Anne and Faouzi, Mohamed and Rochat, Isabelle and Blanchon, Sylvain},
  title = {Impact of Elexacaftor‐Tezacaftor‐Ivacaftor on Quality of Life in Children With Cystic Fibrosis},
  journal = {Pediatric Pulmonology},
  year = {2026},
  volume = {61},
  number = {1},
  doi = {10.1002/ppul.71461}
}
Start for free →